Delving into the Latest Updates on YKYY013 with Synapse

Overview

Basic Info

Drug Type

siRNA

Synonyms-

Target

HBsAg

Action

inhibitors

Mechanism

HBsAg inhibitors(HBsAg inhibitors)

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication

Hepatitis B, ChronicHepatitis B

Inactive Indication-

Originator Organization

Yuekang Pharmaceutical Group Co., Ltd.

Active Organization

Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd.

Yuekang Pharmaceutical Group Co., Ltd.

Hangzhou Tianlong Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.

login

or

view full example data

Boost your research with our RNA technology data.

[Translation] A Phase I clinical study evaluating the safety, tolerability, and pharmacokinetics of YKYY013 in healthy volunteers with a single dose, and the safety, tolerability, pharmacokinetics, and preliminary efficacy of YKYY013 with multiple doses in patients with chronic hepatitis B virus infection.

主要目的：评估 YKYY013 在健康志愿者和在慢性乙型肝炎病毒（HBV）感染患者中的安全性和耐受性。次要目的： 1) 评估 YKYY013 在健康志愿者和在慢性 HBV 感染患者中的药代动力学（PK）特征； 2) 评估 YKYY013 在慢性 HBV 感染患者中的初步疗效； 3) 评估 YKYY013 在健康志愿者和在慢性 HBV 感染患者中的免疫原性。探索性目的： 1) 评估 YKYY013 在健康志愿者中的血药浓度对 QTc 间期的影响。 2) 评估 YKYY013 在慢性 HBV 感染患者中的药效学（PD）特征。

[Translation]

Primary Objective: Evaluate the safety and tolerability of YKYY013 in healthy volunteers and patients with chronic hepatitis B virus (HBV) infection. Secondary Objectives: 1) Evaluate the pharmacokinetic (PK) characteristics of YKYY013 in healthy volunteers and patients with chronic HBV infection; 2) Evaluate the preliminary efficacy of YKYY013 in patients with chronic HBV infection; 3) Evaluate the immunogenicity of YKYY013 in healthy volunteers and patients with chronic HBV infection. Exploratory Objectives: 1) Evaluate the effect of YKYY013 plasma concentrations on the QTc interval in healthy volunteers; 2) Evaluate the pharmacodynamic (PD) characteristics of YKYY013 in patients with chronic HBV infection.

Start Date13 Nov 2025

Sponsor / Collaborator

Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd.

[+1]

100 Clinical Results associated with YKYY013

Login to view more data

100 Translational Medicine associated with YKYY013

Login to view more data

100 Patents (Medical) associated with YKYY013

Login to view more data

100 Deals associated with YKYY013

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis B, Chronic	Phase 1	China	Hangzhou Tianlong Pharmaceutical Co., Ltd.	13 Nov 2025
Hepatitis B, Chronic	Phase 1	China	Beijing Yuekang Kechuang Pharmaceutical Technology Co., Ltd.	13 Nov 2025
Hepatitis B	Preclinical	China	Yuekang Pharmaceutical Group Co., Ltd.	15 Mar 2025